Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L M Dreosti

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Leukemia & Lymphoma|April 1, 1994
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemiaL M Dreosti, W Bezwoda, K Gunter
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|April 10, 1982
Thyrotoxicosis presenting as dysphagia. A case reportR H Ming, L M Dreosti, L O Tim, et al.
Blood Cancer Journal|July 30, 2016
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimenS J Jacobus, S V Rajkumar, M Weiss, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Leukemia & Lymphoma|April 1, 1994
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemiaL M Dreosti, W Bezwoda, K Gunter
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|April 10, 1982
Thyrotoxicosis presenting as dysphagia. A case reportR H Ming, L M Dreosti, L O Tim, et al.
Blood Cancer Journal|July 30, 2016
Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimenS J Jacobus, S V Rajkumar, M Weiss, et al.
Pageof 1